PTC Therapeutics Inc. (PTCT)
NASDAQ: PTCT
· Real-Time Price · USD
57.26
-0.75 (-1.29%)
At close: Sep 05, 2025, 3:59 PM
57.26
0.00%
After-hours: Sep 05, 2025, 04:42 PM EDT
PTC Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue Revenue | 2.94M | 986.23M | 465.53M | 135.42M | 133.22M | 103.11M | 91.28M | 107.26M | 82.71M | 75.24M | 68.2M | 81.41M | 71.37M | 85.48M |
| Collaboration and License Revenue Revenue Growth | -99.70% | +111.85% | +243.76% | +1.65% | +29.20% | +12.96% | -14.90% | +29.68% | +9.93% | +10.33% | -16.23% | +14.06% | -16.50% | n/a |
| Product Revenue | 118.33M | 153.43M | 142.5M | 61.37M | 53.18M | n/a | n/a | 4.09M | 696K | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | -22.88% | +7.67% | +132.22% | +15.38% | n/a | n/a | n/a | +487.64% | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue | 57.6M | 36.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | +58.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States Revenue | 36.35M | 117.96M | 67.4M | 65.7M | 54.6M | 58.2M | 54.8M | 56.8M | 48.6M | 47.5M |
| United States Revenue Growth | -69.18% | +75.02% | +2.59% | +20.33% | -6.19% | +6.20% | -3.52% | +16.87% | +2.32% | n/a |
| Non-Us Revenue | 81.98M | 343.96M | 76.6M | 96.5M | 115.1M | 55.7M | 76.6M | 77M | 79.2M | 69.7M |
| Non-Us Revenue Growth | -76.17% | +349.04% | -20.62% | -16.16% | +106.64% | -27.28% | -0.52% | -2.78% | +13.63% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 85.26M | 80.96M | 84.68M | 73.46M | 69.5M | 73.27M | 76.29M | 80.89M | 88.45M | 86.91M | 92.72M | 80.12M | 79.89M | 73.27M | 86.55M | 69.25M | 68.88M | 61.09M | 75.46M | 57.84M | 53.66M | 58.21M | 63.5M | 49.28M | 49.22M | 40.54M | 48.67M | 38.37M | 33.55M | 32.97M | 35.48M | 31.42M | 28.87M | 25.5M | 24.17M | 23.65M | 23.37M | 25.94M | 25.89M | 21.37M | 17.21M | 17.61M |
| Selling, General, and Administrative Revenue Growth | +5.31% | -4.40% | +15.28% | +5.69% | -5.15% | -3.96% | -5.68% | -8.55% | +1.77% | -6.26% | +15.73% | +0.28% | +9.04% | -15.34% | +24.98% | +0.54% | +12.74% | -19.03% | +30.46% | +7.79% | -7.82% | -8.33% | +28.84% | +0.14% | +21.39% | -16.69% | +26.84% | +14.38% | +1.75% | -7.08% | +12.92% | +8.86% | +13.20% | +5.49% | +2.19% | +1.23% | -9.92% | +0.20% | +21.15% | +24.16% | -2.30% | n/a |
| Research and Development Revenue | 112.99M | 108.97M | 124.77M | 161.41M | 132.17M | 116.13M | 121.35M | 164.21M | 185.87M | 195.12M | 188.69M | 165.46M | 157.26M | 140.08M | 149.84M | 130.84M | 125.48M | 134.51M | 118.01M | 93M | 176.53M | 90.11M | 81.83M | 63.08M | 59.98M | 52.57M | 53.65M | 54.37M | 32.61M | 31.36M | 29.23M | 30.02M | 30.84M | 27.36M | 26.01M | 31.4M | 28.83M | 31.4M | 35.05M | 30.64M | 28.19M | 27.94M |
| Research and Development Revenue Growth | +3.69% | -12.66% | -22.70% | +22.13% | +13.81% | -4.30% | -26.10% | -11.65% | -4.74% | +3.41% | +14.04% | +5.21% | +12.27% | -6.52% | +14.52% | +4.27% | -6.71% | +13.98% | +26.90% | -47.32% | +95.91% | +10.11% | +29.73% | +5.16% | +14.10% | -2.02% | -1.33% | +66.74% | +3.97% | +7.28% | -2.63% | -2.63% | +12.69% | +5.20% | -17.15% | +8.91% | -8.19% | -10.41% | +14.39% | +8.69% | +0.90% | n/a |